3,450 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Triglav Skladi D.O.O.

Triglav Skladi D.O.O. acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,450 shares of the pharmaceutical company’s stock, valued at approximately $1,389,000.

Several other hedge funds and other institutional investors have also modified their holdings of VRTX. Brown Lisle Cummings Inc. purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $30,000. Sugar Maple Asset Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $35,000. Golden State Wealth Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $37,000. Truvestments Capital LLC raised its holdings in shares of Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock worth $40,000 after acquiring an additional 23 shares in the last quarter. Finally, Midwest Capital Advisors LLC bought a new position in Vertex Pharmaceuticals during the fourth quarter valued at about $41,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Up 1.0%

VRTX stock opened at $438.65 on Monday. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company has a market cap of $112.64 billion, a PE ratio of -199.39, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. The business’s 50-day simple moving average is $482.97 and its 200 day simple moving average is $464.36. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same period last year, the business earned $4.76 earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Wells Fargo & Company lowered Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 target price on the stock. in a report on Thursday, January 30th. StockNews.com upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 11th. BMO Capital Markets set a $545.00 target price on Vertex Pharmaceuticals in a report on Friday, January 31st. Finally, Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Thirteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $515.04.

Insider Buying and Selling

In related news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at $13,256,000. This trade represents a 10.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Ourania Tatsis sold 530 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $475.34, for a total value of $251,930.20. Following the sale, the executive vice president now directly owns 58,539 shares in the company, valued at approximately $27,825,928.26. This trade represents a 0.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,005 shares of company stock valued at $1,978,465 over the last three months. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.